Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DRI Healthcare TrustDHTRF 33 Net Margin % is 14.51% as of Jun. 2026, which is 0% below its 10-year median of 14.52. GuruFocus rates DHTRF with a GF Score™ of 33/100 and a GF Value™ of $14.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 958 Drug Manufacturers companies, DRI Healthcare Trust ranks worse than 81.63% on this metric.
DRI Healthcare Trust (OTCPK:DHTRF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
DRI Healthcare Trust Net Margin % Related Terms
DRI Healthcare Trust Net Margin % Historical Data
* Premium members only.
The historical data trend for DRI Healthcare Trust's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, DRI Healthcare Trust's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DRI Healthcare Trust Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, DRI Healthcare Trust's Net Margin % distribution charts can be found below:
* The bar in red indicates where DRI Healthcare Trust's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRI Healthcare Trust (DHTRF) has a Net Margin % of 14.51% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on DRI Healthcare Trust and its competitors. This is near median its historical median of 14.52. According to the industry distribution chart, DRI Healthcare Trust ranks #782 out of 958 companies in the Drug Manufacturers industry, placing it in the top 81.6%.
Is DRI Healthcare Trust's Net Margin % too high?
DRI Healthcare Trust's current Net Margin % of 14.51% is near median its 10-year median of 14.52. The Drug Manufacturers industry median Net Margin % is 5.41. DRI Healthcare Trust's value of 14.51% is 168.2% above this industry median. Based on the distribution chart, DRI Healthcare Trust ranks #782 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, DRI Healthcare Trust has a GF Score™ of 33/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DRI Healthcare Trust's Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, DRI Healthcare Trust ranks #782 out of 958 companies for Net Margin %. This places DRI Healthcare Trust in the lower half of its industry. The industry median Net Margin % is 5.41. DRI Healthcare Trust's value of 14.51% is 168.2% above this benchmark. While the company's 10-year median is 14.52 vs. the industry median of 5.41, DRI Healthcare Trust has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.41, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DRI Healthcare Trust's current Net Margin % of 14.51% is 168.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on DRI Healthcare Trust and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DRI Healthcare Trust's current Net Margin % is 14.51%, which is near median its own 10-year median of 14.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DRI Healthcare Trust stock overvalued right now?
Based on GuruFocus' analysis, DRI Healthcare Trust (DHTRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $14.06, compared to a current price of $12.70 — trading 9.7% below its estimated fair value. The current Net Margin % is 14.51%, which is near median its 10-year median of 14.52 and 168.2% above the Drug Manufacturers industry median of 5.41. DRI Healthcare Trust's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For DRI Healthcare Trust (DHTRF), the current Net Margin % is 14.51% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DRI Healthcare Trust (DHTRF) Overvalued in 2026?
Based on GuruFocus' analysis, DRI Healthcare Trust stock appears to be undervalued.
The current stock price of $12.70 is trading 9.7% below its estimated GF Value™ of $14.06.
GuruFocus considers DRI Healthcare Trust to be Modestly Undervalued.
Key valuation signals for DHTRF:
Net Margin %: 14.51% (near median its 10-year median of 14.52)
GF Value™: $14.06 vs. price of $12.70 (9.7% below fair value)
Industry Position: 168.2% above the Drug Manufacturers median (#782 of 958)
No single metric tells the full story. See the DHTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DRI Healthcare Trust is an open-ended trust that purchases royalty entitlements on products that address unmet medical needs, providing its unitholders with top-line exposure to a portfolio of therapeutics. Its portfolio comprises several royalty streams on products that treat conditions in a number of therapeutic areas, including oncology, neurology, ophthalmology, endocrinology, hematology, dermatology, as well as lysosomal storage disorders (LSD) and immunology. The Trust has concluded that it operates as one segment, focused on acquiring royalty assets. Geographically, it generates maximum royalty income from the sale of products underlying its royalty agreements in the United States, followed by other markets such as Japan, the European Union, and the rest of the world.
33GF Score
Get the complete analysis for DHTRF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHTRF has been successfully added to your 
